La cadena de opciones muestra datos clave de las opciones de acciones de Sutro Biopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Sutro Biopharma..

Sutro Biopharma (NASDAQ:STRO) Bolsa, Cadena de Opciones

Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma Inc

Strong

STRONG GLOBAL ENTMT INC CL A COM VOTING SHS

Stroeer SE & Co KGaA

STROEER SE CO UNSP/ADR by Stroeer SE and Co

Stronghold Digital Mining, Inc. - Class A Common Stock

Stronghold Digital Mining Inc

Stronghold Token

STROUD RESOURCES LTD by Stroud Resources Ltd.

Stroud Resources Ltd

DA Davidson analyst Brian Holland maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $164 to $149.

News

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Hershey, Lowers Price Target to $149

Management

Cemex CEO Fernando González Decides To Retire; Jaime Muguiro Appointed As New CEO, Effective April 1, 2025

Guidance

Spirit AeroSystems Expects Continued Operational Environment And Higher Delivery Rates To Drive Better Results In 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and lowers the price target from $80 to $75.

Reiteration

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $75

Canaccord Genuity analyst Brian McNamara maintains Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Buy and lowers the price target from $15 to $14.

Canaccord Genuity Maintains Buy on Newell Brands, Lowers Price Target to $14

Revenue decreased from the fourth quarter of 2023, primarily due to the impacts from the Boeing Memorandum of Agreement (MOA) executed in October&nbsp;2023 recognized in the fourth quarter of 2023, including favorable pricing adjustments on the Boeing 787 program and the reversal of the potential claim related to the Boeing 737 vertical fin attach fittings issue, partially offset by higher Defense and Space revenues in the fourth quarter of 2024.&nbsp;
Overall deliveries increased during the fourth quarter of 2024 compared to the same period of 2023, including higher Boeing 737 deliveries.
Gross loss was recognized in the fourth quarter of 2024 compared to gross profit for the same period of 2023. The operating income recognized in the fourth quarter of 2023 included the favorable impact of the Boeing MOA executed in October&nbsp;2023 to the Boeing 787 program, including favorable change in estimates as well as a material right obligation liability reversal.

Spirit AeroSystems Says Merger With Boeing On Track To Close In Mid-2025

Spirit AeroSystems Q4 Preliminary Net Revenues $1.662B Vs $1.813B Last Year; Est $1.614B

HC Wainwright &amp; Co. analyst Ed Arce downgrades Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Buy to Neutral.

Downgrades

PLRX

HC Wainwright & Co. Downgrades Pliant Therapeutics to Neutral

Bozeman has served as President and Chief Executive Officer, and a director, of C.H. Robinson since 2023.&nbsp;

3M Adds David Bozeman To Board, Amy Hood Does Not Intend To Stand For Reelection

Michael F. Roman, Executive Chairman of the Board of Directors, has announced his intention to retire as Executive Chairman, and as a Director, effective March 1, 2025.&nbsp; Mr. Roman has agreed to continue to serve as Executive Advisor to the Board until his retirement from 3M on May 1, 2025.&nbsp;

3M Names William Brown, Its CEO And Director, To Serve As Its Chairman, Effective March 1, 2025 In Addition To His Current Responsibilities

SPACE

Contracts

General

GSAT

MDA Space Has Signed A Definitive Contract With Globalstar To Be The Prime Contractor For The Satellite Operator's Next-Generation Low Earth Orbit Constellation, With A Total Contract Value Of Approximately $1.1B

Ancora Issues Letter To US Steel's Board; Says Independent Slate and Alan Kestenbaum Are Ready to Lead Multibillion-Dollar Capital Investment Program to Revitalize Company

TRX Gold Secures New Financing Agreements With Stanbic And Auramet To Boost Liquidity, Expand Growth Opportunities

Needham analyst Mike Cikos reiterates Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) from Hold to Hold.

Needham Reiterates Hold on Dynatraceto Hold

President Donald Trump announced on Sunday that he will impose new 25% <a href="https://www.benzinga.com/markets/equities/25/02/43583123/trump-to-announce-25-steel-and-aluminum-tariffs-economist-warns-president-is-making-us-manufacturing-globally-uncompetitive">tariffs</a> on all steel and aluminum imports, adding to existing duties, in a further escalation of his trade policy. While this could impact domestic steel and aluminum companies, investors can consider the following list of exchange-traded funds (ETFs) to trade following the development.
What Happened: On his way to the NFL Super Bowl in New Orleans, Trump spoke to reporters on Air Force One, and said he would reveal the <a href="https://www.benzinga.com/markets/equities/25/02/43583123/trump-to-announce-25-steel-and-aluminum-tariffs-economist-warns-president-is-making-us-manufacturing-globally-uncompetitive">new tariffs</a> on Monday, followed by reciprocal tariffs on Tuesday or Wednesday, matching the rates imposed by other countries.
Tariffs impact domestic companies by influencing costs, competitiveness, and supply chains
According to a report by the First National Bank of Omaha and the think tank Council on Foreign Relations, the negative effects of tariffs include increased input costs, reduced competitiveness, disruption in supply chains, retaliation, diversion in investment, and reduced consumer spending. On the positive side, tariffs may temporarily protect domestic industries and generate government revenue.
Investors should look out for the following metal ETFs as Trump is likely to impose tariffs on imports.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Fund Name</td>
<td>AUM</td>
<td>Expense Ratio</td>
<td>Six Month Returns</td>
</tr>
<tr>
<td>VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>)</td>
<td>$75.23 million</td>
<td>0.56%</td>
<td>-4.88%</td>
</tr>
<tr>
<td>Invesco DB Base Metals Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBB#NYSE">DBB</a>)</td>
<td>$112.4 million</td>
<td>0.79%</td>
<td>2.39%</td>
</tr>
<tr>
<td>iShares U.S. Basic Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYM#NYSE">IYM</a>)</td>
<td>$534.51 million</td>
<td>0.39%</td>
<td>-0.68%</td>
</tr>
<tr>
<td>SPDR S&amp;P Metals and Mining ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XME#NYSE">XME</a>)</td>
<td>$1623.5 million</td>
<td>0.35%</td>
<td>5.00%</td>
</tr>
</tbody>
</table>
</figure>
Iron ore, a key ingredient in steelmaking, saw its prices rise 0.71% in Singapore around 3:43 p.m. local time, while aluminum futures on the Comex gained 0.49%.
See Also: <a href="https://www.benzinga.com/markets/equities/25/02/43583123/trump-to-announce-25-steel-and-aluminum-tariffs-economist-warns-president-is-making-us-manufacturing-globally-uncompetitive">Trump To Announce 25% Steel And Aluminum Tariffs — Economist Warns President Is &#8216;Making US Manufacturing Globally Uncompetitive&#8217;</a> 
Why It Matters: Although Trump initially paused tariffs on Canada and Mexico, he has renewed threats by specifically targeting metals in his media interactions on Sunday.
According to the American Iron and Steel Institute&#8217;s January <a href="https://www.steel.org/2025/02/aisi-releases-january-sima-imports-data-4/">data</a>, the U.S. gets most of its imported steel from Canada, Brazil, and Mexico, followed by South Korea and Vietnam. 
&#8220;Canadian steel and aluminum support key industries in the U.S., from defence, shipbuilding, and auto,&#8221; said the Canadian Minister of Innovation, Science and Industry, Francois-Philippe Champagne, in an X post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Let's all be clear. Canadian steel and aluminum support key industries in the U.S. from defence, shipbuilding and auto. This is making North America more competitive and secure. We will continue to stand up for Canada, our workers, and our industries. <a href="https://t.co/NBFeU6Y8zN">pic.twitter.com/NBFeU6Y8zN</a>
&mdash; François-Philippe Champagne (FPC) &#x1f1e8;&#x1f1e6; (@FP_Champagne) <a href="https://twitter.com/FP_Champagne/status/1888754195727106310?ref_src=twsrc%5Etfw">February 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Citing the risks of these metal tariffs, Joseph Brusuelas, the principal and chief economist at RSM US said that other countries could follow to protect their economies, and a much larger trade war could ensue after these impositions by Trump.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">US-China Trade War: With Trump set to announce 25% tariffs on aluminum &amp; steel imports and the Chinese imposing $14 billion on trade taxes on U.S. good it is likely that a series of tit-for-tat retaliation has begun. A look at relative yield differentials between the US and… <a href="https://t.co/ACWRKgzlmg">pic.twitter.com/ACWRKgzlmg</a>
&mdash; Joseph Brusuelas (@joebrusuelas) <a href="https://twitter.com/joebrusuelas/status/1888728283392667924?ref_src=twsrc%5Etfw">February 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">DeepSeek&#8217;s Hedge Fund Owner Had Multiple Top Projects Before Creating The Firm That Fueled $1 Trillion Market Cap Erosion Of AI Stocks</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Politics

Economics

Markets

ETFs

iShares Trust Dow Jones US Basic Materials Sector Index Fund

Donald Trump's Expected Tariffs On Aluminum, Steel Imports May Impact Domestic Companies: Here's A List Of Metal ETFs That Could Be Affected

Raymond James analyst John Freeman downgrades ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Strong Buy to Outperform and lowers the price target from $157 to $124.

Raymond James Downgrades ConocoPhillips to Outperform, Lowers Price Target to $124

HC Wainwright &amp; Co. analyst Yi Chen maintains Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) with a Buy and raises the price target from $11 to $12.

SRTS

HC Wainwright & Co. Maintains Buy on Sensus Healthcare, Raises Price Target to $12

On Friday, February 7, U.S. markets closed lower after Trump announced plans for reciprocal tariffs amid weak jobs data and declining consumer sentiment. Despite early struggles, strong earnings provided some support. Consumer sentiment hit a seven-month low, inflation expectations surged, and job growth slowed, reinforcing expectations that the Fed will delay rate cuts until June.
The University of Michigan reported a sharp rise in inflation expectations, with the one-year outlook hitting 4.3%, the highest since November 2023. February&#8217;s jobs report showed mixed results: job growth slowed, but unemployment dropped more than expected, and wages surged.
All S&amp;P 500 sectors ended in the red, led by losses in communication services, consumer discretionary, and materials stocks.
The Dow Jones Industrial Average was down 0.99% and closed at 44,303.40, the S&amp;P 500 closed lower by 0.95% at 6,025.99, and the Nasdaq Composite fell 1.36% to finish at 19,523.40.
Aisa Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 closed lower by 0.12% at 38,770.50, led by losses in the Glass, Retail and Real Estate sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 declined 0.34% to 8,482.80, led by losses in the IT, Telecoms Services and Materials sectors.</li>
<li>India&#8217;s Nifty 50 closed lower by 0.78% at 23,376.05, and Nifty 500 slid 1.32%, closing at 21,360.55, led by losses in the Real Estate, Metals, and Consumer Durables sectors.</li>
<li>China&#8217;s Shanghai Composite rose 0.56% and closed at 3,322.17, and Shanghai Shenzhen CSI 300 was up 0.21% at 3,901.06.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session higher by 1.84% at 21,521.98.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 0.37%.</li>
<li>Germany&#8217;s DAX rose 0.31%.</li>
<li>France&#8217;s CAC gained 0.26%.</li>
<li>U.K.&#8217;s FTSE index 100 traded higher by 0.47%</li>
<li>European stocks opened higher on Monday despite Trump&#8217;s new tariff announcement. Markets remain optimistic amid strong earnings growth, cheap valuations, and hopes for ECB easing. Nokia appointed Justin Hotard as its new CEO.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 1.17% at $71.81/bbl, and Brent was up 1.15% at $75.50/bbl.</li>
<li>Oil prices rose, rebounding from last week&#8217;s losses amid trade war concerns. Sanctions on Russia and Iran add upside risks, but analysts expect oil to trade lower, with Brent forecasted at $60-$65 per barrel in late 2025.</li>
<li>Natural Gas gained 3.35% to $3.420.</li>
<li>Gold was trading higher by 1.46% at $2,930.21, Silver was up 0.95% to $32.750, and Copper rose 0.69% to $4.6200.</li>
<li>Gold hit record highs as Trump&#8217;s new tariffs fueled safe-haven demand. Markets remain cautious over potential trade war escalation, while strong U.S. inflation data and high interest rates could limit further gold gains.</li>
</ul>
U.S. Futures at 05:30 AM ET
<ul>
<li>Dow futures were up 0.28%, S&amp;P 500 futures gained 0.40%, and Nasdaq 100 futures rose 0.62%.</li>
<li>U.S. stock futures rose, led by steelmakers after Trump announced new tariffs. Investors remain cautious but less reactive to trade moves.</li>
</ul>
Forex at 05:30 AM ET
The U.S. Dollar Index gained 0.10% to 108.15, USD/JPY was up 0.52% to 152.19, and USD/AUD fell 0.14% to 1.5921.
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Advances, Gold Hits Record High On Safe-Haven Demand - Global Markets Today While US Slept

Needham analyst Mike Cikos reiterates Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Buy and maintains $50 price target.

TENB

Needham Reiterates Buy on Tenable Holdings, Maintains $50 Price Target

Jones Trading analyst Jason Weaver maintains Alpine Income Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Buy and maintains $22 price target.

PINE

Jones Trading Maintains Buy on Alpine Income Prop Trust, Maintains $22 Price Target

Finding Winners In Biotech, Probably The Riskiest Sector

Sutro Biopharma (STRO) announced the selected dose from the dose-optimization portion of REFRalphaME-O1, the registration-directed trial of luvelta...

Sutro Biopharma announces selected doses from REFRalphaME-O1

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of $17.00. ...

Strong Buy Rating for Sutro Biopharma Amid Promising Trial Results and Strategic Financial Position

Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Sutro Biopharma (STRO – Research Report). The associated pri...

Promising Developments in Sutro Biopharma's Luvelta Drive Buy Rating

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Sutro Biopharma (STRO – Research Report), with a price target of $4.00. Derek Archil...

Cautious Hold Rating on Sutro Biopharma Amid Mixed Luvelta Outlook and Delayed Timeline

TD Cowen analyst Tara Bancroft maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today. The company's shares closed yesterday at ...

TD Cowen Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro's proprietary cell-free expression tech...

Sutro Biopharma, Boehringer announce application of Sutro's technology

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of...

Sutro Biopharma (STRO) Gets a Buy from Bank of America Securities

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price tar...

Sutro Biopharma: Strategic Partnerships and Promising Pipeline Drive Buy Rating

ABBV

AZNCF

BPMC

LPTX

STRO

SWTX

TARS

VYGR

Press Releases

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Small Cap

Opinion

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Earnings

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

Comments

Sutro Biopharma

Sutro Biopharma (STRO) Opciones

Sutro Biopharma (NASDAQ:STRO) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL